Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Novartis' Pluvicto (lutetium vipivotide tetraxetan) wins FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer label expansion
Radioligand therapy, cancer, prostate cancer, PSMA target, metastatic hormone-sensitive prostate cancer - Read more

PharmaMar's Zepzelca (lurbinectedin) approved in Canada, Qatar, South Korea for first-line extensive-stage small cell lung cancer maintenance
Small molecule, cancer, combination therapy, small cell lung cancer, PD-L1 inhibitor, lurbinectedin - Read more

Fujifilm, Taiho Pharmaceutical partner to develop next-generation ADC manufacturing technologies using AraLinQ platform
Manufacturing agreement, antibody-drug conjugate, biologics, co-development, drug discovery - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

AbbVie raises 2026 revenue forecast to $67.6B on Skyrizi, Rinvoq immunology growth
Small molecule, autoimmune, revenue impact, major transaction - Read more

BlossomHill Therapeutics plans $111.7M IPO to fund EGFR-targeting Tagrisso challenger development
Oncology, small molecule, EGFR, non-small cell lung cancer, clinical-stage - Read more

Ratio Therapeutics closes $70M Series C, advancing radiotherapeutics pipeline and ATLAS trial
Radiopharmaceuticals, oncology, alpha emitter, radioligand therapy, clinical-stage - Read more

Cocrystal Pharma raises $5M private placement from OPKO Health, advancing norovirus program
Antiviral, infectious disease, small molecule, clinical-stage - Read more

Sandoz agrees to pay nearly $500M to settle US generic drug antitrust pricing claims from states
Generics & biosimilars, antitrust, financial, major transaction - Read more

Supernus Pharmaceuticals, Indivior Pharmaceuticals merge in all-stock deal, creating $2.2B CNS company with 11 approved drugs
Small molecule, neurological, major transaction, cost reduction - Read more

Obsidian Therapeutics completes merger with Galera Therapeutics and closes $350M private placement financing
TIL cell therapy, oncology, major transaction, strategic - Read more

AstraZeneca, Bristol Myers Squibb reportedly in early-stage merger talks valuing combined entity at $400B
Merger, oncology, strategic, major transaction - Read more

Curium to merge with Lantheus in $8B radiopharma deal, expanding US diagnostics and theranostics footprint
Radiopharmaceutical, oncology, strategic, major transaction - Read more

HRSA advances revised 340B Rebate Model Pilot Program amid strong hospital opposition
340B program, healthcare policy, operational, financial - Read more

Biocon launches Yesafili biosimilar to Regeneron's Eylea 2 mg in the U.S. market
Biosimilar, ophthalmology, commercial launch, revenue impact - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Amgen discloses material cybersecurity breach exposing patient health data and proprietary company information
Cybersecurity, data privacy, operational, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here